A persistent gap exists where academic innovators develop brilliant science but fail to articulate how it becomes a product. Investors can't fund technology 'thrown over the transom'; they need to see a clear Target Product Profile (TPP) and a path to a return on investment, even at the earliest stages.

The transition from academia to entrepreneurship is most successful when the focus shifts from pure science or technology to solving a tangible, pre-existing clinical problem. This ensures market interest, clinical adoption, and ultimately, patient impact from the outset.

A common pitfall for founders transitioning from a PhD is creating pitch decks that are essentially scientific presentations. Investors are less interested in how the technology works and more interested in the magnitude of the problem it solves and the market's demand for that solution. The 'what' and 'why' trump the 'how'.

When evaluating founders coming from academia, VCs should distinguish between those fixated on a niche problem and those driven by real-world impact. The latter are more likely to find a problem that generates revenue and successfully transition from a science project to a viable company.

With AI tools enabling anyone to build a product, technical execution is no longer a reliable signal for VCs. This creates a rise in "grifters," forcing investors to filter for deeper traits like authentic obsession, high learning velocity, and a compelling "why" behind their mission.

While product and market are crucial, the most important factor in an early-stage bet is the founder. This is because most startups pivot significantly. A resilient, adaptable founder who can execute through change is more valuable than a perfect initial idea, leading to the ranking: Founder > Market > Product.

To attract investment, founders must translate their science into a business case. This involves articulating the target customer, go-to-market strategy, cost structure, and value proposition. Investors back ventures that connect three key elements: strong science, a clear clinical need, and a credible business model.

While passion for helping patients is a powerful motivator, founders must learn to frame their pitch around value creation for investors. This means explicitly connecting the science and clinical benefit to the commercial market, reimbursement strategy, and ultimate financial return for their limited partners.

A common founder mistake is to lead with a product or drug idea. However, a specialist investor's initial focus is on the founder's ability to deeply and clearly articulate the problem or gap they are addressing. The elegance of the proposed solution is evaluated only after the problem is well-defined.